Hormone Receptor Positive Malignant Neoplasm of Breast
20
4
6
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 20 trials
100.0%
+13.5% vs benchmark
15%
3 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (20)
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
A Study of Revaree Plus in People With Breast Cancer
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
Comparison of the Breast Tumor Microenvironment
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
Prospective Thinking in Hormone-Responsive Breast Cancer
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer